Active Biotech and Avidex Conclude Phase I Clinical Trials
Active Biotech AB and Avidex have announced that the product candidate, RhuDex, has completed two Phase I studies looking at safety, tolerability and pharmacokinetics in normal, healthy volunteers.
Avidex will now be starting a dose-escalating, double blind pilot phase I/II study in rheumatoid arthritis, RA, patients. The study is designed to investigate safety, pharmacokinetics and drug interactions in patients and is expected to start recruitment beginning in mid 2006.
For Active Biotech, the agreement with Avidex entailed an initial payment in 2002 and eligibility for milestone payments totalling up to EUR 8,5 million and royalties on future sales. Active Biotech received a milestone payment from Avidex when the Phase I study was initiated first half 2005.
For further information please contact:
Sven Andréasson,
President & CEO
Tel: +46 46 19 20 00
Active Biotech is a publicly traded Swedish biotechnology company. The company has five projects in clinical development for the treatment of serious autoimmune/inflammatory diseases and cancer. Laquinimod - a novel oral treatment of multiple sclerosis – is developed through a cooperation with Teva ...